Category Archives: healthcare

NICE in Conflict-of-Interest Controversy

They say the road to hell is paved with good intentions. The row in the UK over NICE’s call to doctors to increase the use of statins looked to be good example of this handy aphorism. That was until things took a potentially darker turn.
Also posted in Europe, pricing | Tagged , , , | Leave a comment

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in Biotech, FDA, Guest Blog, Legal, Market Access, Marketing, pricing, Regulatory, Strategy | Tagged , , | 1 Comment

The First Footfall: What Apple’s “HealthKit” Announcement Means to Healthcare

By Bill Drummy, Pharm Exec Editorial Advisory Board. Among the many announcements Apple made earlier this month at its annual World Wide Developer’s Conference, one was of particular interest to the healthcare industry. Apple unveiled “HealthKit”, which is really a developer’s toolbox that allows makers of health and medical devices (e.g. Fitbit, UP, Misfit, iHealth) to […]
Also posted in Guest Blog, Technology | Tagged , , , , | Leave a comment

Does Pharma Have the Skills for Consumer Health?

By Michael Winter, Egon Zehnder. Consumer health, the business of selling health and wellness sustaining-brands in categories as diverse as pain relievers, brain-boosting yogurts, sports nutrition, baby food and bone supplement drinks, is poised to take off globally. With consumers becoming ever more health-aware and knowledgeable, companies from both the pharma and consumer segments are […]
Also posted in Guest Blog, Op-Ed, People | Tagged , , | Leave a comment

Sanofi Responds to UK’s Value-Based Assessment Plans

By Leela Barham. The UK’s National Institute for Health and Care Excellence (NICE) set out their proposals for value-based assessment (VBA) in March 2014.  VBA is what value-based pricing (VBP) has essentially morphed into. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 […]
Also posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta